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 Abstract 
X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency disorder caused by 
mutation in the gene encoding the CD40 ligand (CD40L) expressed on activated T cells. Prenatal 
genotyping in carriers with twin pregnancies is more challenging than in women with single 
pregnancies. In addition, women with twin pregnancies may decide on selective termination for 
which the risk of loss of the healthy fetus may exceed 7%. We report here on a family affected by 
XHIGM. Diagnosis of the disease was made in a male patient as late as 33 years of age. After family 
screening the sister of the proband conceived male twins in 2 consecutive pregnancies. In the first 
pregnancy, one of the male fetuses was hemizygous for the c.521A>G (Q174R) mutation in the 
CD40L gene. In the second pregnancy, ultrasound scan showed one fetus to have exencephaly and 
karyotyping revealed this fetus to have trisomy 18. Several options were discussed, but the parents 
decided on selective termination in both pregnancies. The interventions were successful in both cases 
and the mother now has two healthy sons. This report demonstrates the way in which advanced 
technologies in molecular medicine and obstetric interventions may assist families with decisions 
about possible selective termination in cases of life-threatening molecular or chromosomal disorders. 
The diagnosis of CD40L deficiency at the age of 33 year in the proband was striking and indicated 
that PIDs are still neglected as disease entities in the evaluation of patients with recurrent severe 
infectious diseases. 
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Introduction 
 
Studies of different types of inherited hyper-IgM (HIGM) syndromes characterized by defective 
antibody diversification and impaired class switch recombination revealed that intrinsic genetic 
defects in both T cells and B cells may lead to these immunological disorders [1-5]. In particular, 
defects of genes encoding for CD40 ligand (CD40L), CD40, nuclear factor-κB essential modulator, 
activation-induced cytidine deaminase, and uracil-DNA glycosylase have been described as the 
different molecular forms of the multi-faced HIGM syndrome [6-10].  
X-linked HIGM syndrome (XHIGM) is a rare primary immunodeficiency disorder 
characterized by recurrent sinopulmonary and gastrointestinal tract infections, persistent or cyclic 
neutropenia, stomatitis, Pneumocystis jirovecii pneumonia, sclerosing cholangitis and, in rare cases, 
hepatocellular, bile duct carcinoma and neuroendocrine carcinoma [4, 9, 10-12]. XHIGM is caused 
by a mutation of CD40L, which maps to the long arm of the X chromosome and encodes the CD40 
ligand (CD40L), an activation marker expressed on the surface of T cells [8]. Thus, in the absence of 
an HLA-compatible donor long-term survival rate is poor, highlighting the importance of prenatal 
diagnosis in affected families. The identification of the causal gene has opened up possibilities for 
genetic testing by DNA sequencing for affected families. We report here that diagnosis of XHIGM, a 
severe combined primary immunodeficiency may present clinically as a mild disease for decades 
indicating the lack of appropriate awareness of PID. We also present a unique and challenging 
clinical case of subsequent twin pregnancies in a woman with heterozygous mutation in the CD40L 
gene. This report demonstrates how advancement in molecular medicine and obstetric interventions 
may assist families with life-threatening genetic disorders.  
  
 
Subjects and Methods 
 
Subjects.  All the studies described here were approved by the institutional review 
board and informed consent was obtained from family members. The 33-year-old proband 
in the family (Fig. 1) was referred to us, because he had had low concentrations of serum 
immunoglobulin G and A isotypes. He had suffered from recurrent respiratory tract 
infections, including several episodes of pneumonia and pleuropneumonia since early 
childhood. He also had intestinal tract infections and recurrent episodes of neutropenia 
consistent with XHIGM. Immunoglobulin substitution was unreasonably withheld because 
of the lack of serum IgA and a feared risk of anaphylaxis. No case of immunodeficiency or 
unexplained death was identified in the family, his parents, and 28-year-old sister were all 
clinically healthy. Immunophenotyping and DNA sequencing showed the proband to have 
XHIGM and identified his mother and sister as carriers (Fig. 1). After the diagnosis was 
made, the patient was put on regular intravenous immunoglobulin (IVIG) replacement 
therapy with 400 mg/kg dose monthly. Until now the patient refused hematopoietic stem 
cell transplantation. Following the detection of the CD40L gene mutation in the family, the 
proband’s sister decided to undergo prenatal testing when she became pregnant.  
 
Methods. Serum immunoglobulin isotype levels and lymphocyte subpopulations were 
determined by standard immunological assays. Lymphocyte subsets and cell-surface 
expression of CD40L on activated T lymphocytes was analyzed with a Coulter 500 flow 
cytometer.  
  
gDNA was isolated from blood cells or chorionic villus samples (CVS) with the 
QIAamp DNA Blood Mini kit (QIAGEN GmbH, Hilden, Germany).  
PCR amplification and sequencing of exons 1 to 5 and the flanking intron regions of 
the CD40L gene were used to analyze the mutations present [13]. Primer sequences are 
available on request. Amplicons were sequenced with the BigDye Terminator cycle 
sequencing kit (Applied Biosystems, Foster City, CA), and analyzed on an ABI 3130 
capillary sequencer (Applied Biosystems) [14]. Sequence variations are described with 
respect to the reference sequence, GenCard accession no. GC0XP123307 for CD40L 
cDNA, in which the c.1 position corresponds to the A of the ATG translation initiation 
codon.  
 
Results 
 
As shown in Table 1, serum IgM concentrations in the XHIGM patient was normal in 
contrast to the markedly decreased serum IgG and IgA levels. The number of peripheral 
blood lymphocytes and CD3+, CD4+, CD8+, CD19+, and CD56+/CD3- lymphocyte subsets 
were in the normal range in all family members tested. 
CD40L expression by activated T cells using PE-conjugated  monoclonal antibodies was 
studied in normal controls and in members of the affected family (Table 1). Surface expression of 
CD40L by activated T cells was negligible in the proband with XHIGM and intermediate expression 
was detected in the heterozygous sister and mother (Table 1). Positive control experiments showed 
that the majority of T lymphocytes from all family members tested expressed CD69+ suggesting that 
these cells were activated by PMA/ionomycin treatment (Table 1).  
  
Sequence analysis of the CD40L gene in the proband revealed a c.521A>G 
missense mutation in exon 5 predicting a Q174R amino acid replacement in the TNF 
domain of the protein. The mother and the sister of the hemizygous male patient were 
carriers for the mutated CD40L allele, and both of them were clinically and 
immunologically healthy.  
In the first pregnancy, chromosome analysis showed both fetuses to be male, and 
DNA sequencing showed one fetus to be hemizygous for the Q174R mutation in CDL40L 
(Fig. 1). The parents attended several detailed counseling sessions; specifically, they were 
offered genetic HLA typing of the two fetuses to determine whether the unaffected twin 
could act as a stem cell donor for his brother. However, they declined this option and 
eventually opted for selective termination which was performed during the 12th week of 
gestation. DNA isolated from a blood sample drawn from the fetal heart before selective 
termination was sequenced and confirmed hemizygosity for the CDL40L mutation. The rest 
of the pregnancy was uneventful and a healthy male newborn was born at 37 weeks of 
gestation by cesarean section. 
One year later, this woman again conceived male twins, this time without the use of 
fertility treatment (Fig 1). Ultrasound scan in the ninth week of gestation showed 
exencephaly in one of the twins. This malformation is invariably fatal, but chorionic villus 
sampling from both placentas (fused in this case) was nonetheless performed during the 
11th week of gestation. Molecular genetic analysis showed both fetuses to be wild type for 
the CD40L mutation and karyotyping revealed trisomy 18 in the exencephalic fetus. The 
parents again decided on selective termination, which was performed in the 12th week of 
gestation, without complications. The mother gave birth of a male newborn at 38 weeks of 
pregnancy without further complications.  
 
  
Discussion 
 
Advanced technologies in molecular genetics and interventional medicine have greatly contributed to 
the complex management and to a better quality of life of families with deadly diseases caused by 
mutations in PID genes. Identification of the genes responsible for severe PIDs has made direct 
mutational analysis of both affected patients and carriers possible. Genetic counseling and prenatal 
testing can now be offered to families at risk. We report here the case of a patient with Q174R 
mutation who was diagnosed with XHIGM as late as 33 years of age. Hemizygous patients with 
XHIGM typically developed disease manifestations during the first 2 years of life when they present 
mostly with recurrent respiratory tract infections. In addition to defects in T cell mediated immunity 
and low immunoglobulin G and A isotypes, transient neutropenia in XHIGM patients may also 
predisposes them to infectious complications. The male patient described this report had had 
recurrent and severe respiratory tract infections since early childhood and he was diagnosed with 
selective IgA deficiency. The misconception that patients with low or absent serum IgA 
concentration should not receive IVIG has also contributed to the delay of appropriate management 
of this patient. This case provides an example that PIDs are still strikingly neglected diseases in the 
management of patients with recurrent infectious diseases [15]. The patient has been receiving IVIG 
infusions monthly and he has had only mild respiratory tract infections. He refused bone marrow 
transplantation as a primary attempt to cure his disease. Such a refusal attitude of XHIGM patients to 
undergoing BMT may be a more general problem as only a small number of patients registered in the 
ESID registry were transplanted (B. Gathmann, personal communication). A possible reason for not 
using BMT may be the wide heterogeneity of the severity of the disease. Also, transplants are mostly 
done from matched related or unrelated donors who are not always available.     
  
We report here an intriguing and unique case of a woman heterozygous for a CD40L 
mutation who conceived two sets of male twins in consecutive pregnancies. As XHIGM remains a 
life-threatening PID with severe infectious complications and malignancies, poor quality of life and a 
poor prognosis for patients with no HLA-matched sibling, carriers of CD40L mutations need genetic 
testing for family planning. Knowledge that the women is a carrier of the disease has implications for 
the decision to start a pregnancy and may encourage families to make use of prenatal testing and 
other measures, including selective termination, if necessary. Women with one wild-type and one 
hemizygous fetus may decide to continue the pregnancy and analysis of HLA markers may help to 
determine whether the wild-type fetus may be a potential HLA-matched donor, from whom cord 
blood stem cells could be obtained after delivery to treat the affected twin [16]. If the fetuses present 
HLA mismatches, the family may consider stem cell transplantation with cells from an unrelated 
donor. The woman studied here decided to undergo selective termination, for which the risk of loss 
of the healthy fetus is 2.4 to 7.1% [17, 18]. Exencephaly, as diagnosed in one of the fetuses in the 
second pregnancy, is invariably fatal very shortly after birth. This malformation is often associated 
with severe polyhydramnios, increasing the risk of preterm or very preterm delivery of both twins. 
This potential complication justifies the decision of the mother to undergo selective termination. 
Families choosing to undergo prenatal testing may request the information provided 
by these tests to help them to adjust emotionally and to make specific plans and decisions 
as soon as possible. In both pregnancies described here, karyotyping results were available 
within 24 hours, with direct sequencing of the DNA region concerned requiring a further 
48 hours. In the second pregnancy the severe malformation of one of the fetuses was 
detected as early as the 9th week of gestation.  
This report demonstrates the complexity of prenatal diagnosis by ultrasound, 
karyotyping and molecular genetics and also the availability of selective termination in the 
management of discordant twin pregnancies. We also report here that diagnosis of CD40L 
  
deficiency may be delayed by decades indicating the lack of awareness of PIDs in the 
general management of patients with infectious diseases. 
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Table 2. Serum immunoglobulins and lymphocyte subsets 
 
  
Subjects Immunoglobulins (g/L)   Lymphocyte  Lymphocyte subsets (%)    
___________________________        number  ______________________________________________________
  IgG  IgA  IgM   (cells/mm3)  CD3+ CD4+ CD8+ CD19+  CD56+/CD3- CD40La CD69a 
 
 
Probandb  2,10  0,40  0,9  4200   73 36 34 17  8  0.02 85 
Sister  13,2  0,90  0,9  2780   77 51 23 13  9  33.7 91 
Mother 13,3  4,20  0,7  1800   72 53 20 15  13  42.0 95 
Father  10,5  2,90  1,1  3490   78 49 27 10  24  75.3 89 
Normals 7,0-16,0 0,7-4,0  0,4-2,3  >1500   52-78 25-48 9-35 8-24  5-15  >50 >85  
 
 
aPercentage of CD3+CD8- lymphocytes. bhemizygous patient with Q174R mutation in the CD40L gene.  
 
   
   
 
 
 
  
Figure legend 
 
Figure 1.  CD40 ligand (CD40L) mutation and clinical phenotypes. Pedigree 
of the family shows the Q174R amino acid substitution in CD40L 
which was first detected in the proband. His heterozygous sister 
(II/2) conceived two sets of male twins in consecutive pregnancies. 
In the first pregnancy, one of the fetuses (III/3) was hemizygous for 
the mutation, whereas, in the second pregnancy, both fetuses were 
wild type (III/4 and III/5), but one fetus had exencephaly. m, mutant; 
wt, wild type. 
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